

### Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

#### Listing of the Claims:

1.-17. (Cancelled).

18. (Currently Amended) A method of ~~manufacturing a medicament for use in the treatment of~~ treating deregulated angiogenesis in a patient with a disease associated with deregulated angiogenesis, wherein the method comprises the ~~step~~ steps of:

(1) ~~providing~~ administering to a human suffering from the disease an effective amount of a composition comprising a polypeptide selected from the group consisting of:

(a) fibroblast growth factor 23 (FGF-23) (SEQ ID NO: 1) or a bioactive fragment of FGF-23;

(b) a bioactive polypeptide having a percentage of identity of at least 95% with the amino acid sequence of any one of the polypeptides of (a); and

(c) a bioactive variant of any one of the polypeptides of (a) or (b); ~~(b)~~; and

~~(2) manufacturing a medicament comprising the polypeptide and a pharmaceutically acceptable carrier for use in the treatment of a disease associated with deregulated angiogenesis~~ carrier; and

(2) evaluating the effect of the polypeptide on deregulated angiogenesis.

19. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 18, wherein the disease associated with deregulated angiogenesis is selected from the group consisting of: retinopathies, age-related macular degeneration, haemangioblastoma, haemangioma and tumors.

20. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 18, wherein the disease associated with deregulated angiogenesis is retinopathy.

21. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 18, wherein the disease associated with deregulated angiogenesis is a cell proliferative disorder.

22. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 21, wherein the cell proliferative disorder is selected from the group consisting of:  
  
chronic or acute renal diseases, arteriosclerosis, atherosclerosis, psoriasis, endometriosis, diabetes, chronic asthma and cancer.

23. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 21, wherein the cell proliferative disorder is cancer.

24. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 18, wherein the polypeptide is encoded by a first nucleic acid which hybridizes under stringent conditions to a second nucleic acid having the sequence of SEQ ID NO: 3.

25. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 18, wherein the polypeptide comprises a C-terminal fragment of FGF-23.

26. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 25, wherein the polypeptide comprises at least 15 amino acids of the C-terminus of FGF-23.

27. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 25, wherein the polypeptide has an amino acid sequence of SEQ ID NO: 2.

28. (Currently Amended) ~~Use of a polypeptide~~ The method according to claim 25, wherein the polypeptide is encoded by a first nucleic acid which hybridizes under stringent conditions to a second nucleic acid having the sequence of SEQ ID NO: 4.

29.-42. (Cancelled).

43. (New) A method of inhibiting angiogenesis in a human, wherein the method comprises the step of:

administering to a human suffering from a disease associated with deregulated angiogenesis

an effective amount of a medicament comprising a composition comprising a fibroblast growth factor 23 (FGF-23) (SEQ ID NO: 1) or a bioactive fragment or variant of FGF-23, and a pharmaceutically acceptable carrier.

44. (New) The method according to claim 43, wherein the disease associated with deregulated angiogenesis is selected from the group consisting of: retinopathies, age-related macular degeneration, haemangioblastoma, haemangioma and tumors.

45. (New) The method according to claim 43, wherein the disease associated with deregulated angiogenesis affects muscle tissue.

46. (New) The method according to claim 43, wherein the disease associated with deregulated angiogenesis is a cell proliferative disorder.

47. (New) The method according to claim 46, wherein the cell proliferative disorder is selected from the group consisting of:

chronic or acute renal diseases, arteriosclerosis, atherosclerosis, psoriasis, endometriosis, diabetes, chronic asthma and cancer.

48. (New) The method according to claim 46, wherein the cell proliferative disorder is cancer.

49. (New) The method according to claim 43, wherein the polypeptide comprises a C-terminal fragment of FGF-23.

50. (New) The method according to claim 43, wherein the polypeptide comprises at least 15 amino acids of the C-terminus of FGF-23.

51. (New) The method according to claim 43, wherein the polypeptide has an amino acid sequence of SEQ ID NO: 2.